New Business
We are always searching for opportunities that allow for strategic expansion by consolidating our operations in Latin America and expanding into key global markets.
Business Development & Finished Products Licensing
Strategic partnerships with other organizations and companies are fundamental to our growth and innovation strategy. Currently, products arising from partnerships and licenses represent around 10% of the company's total revenue, which is equivalent to approximately R$ 900 million.
In this sense, we constantly search for business opportunities in the various therapeutic areas, for radical or incremental innovative products and technologies. We are prepared to work with different business models, whether distribution or licensing, as well as co-development and technology transfer.
To schedule a meeting and check the possibility of establishing a partnership with us, send an email to: partnership@eurofarma.com
M&A
We are always on the lookout for opportunities that allow for strategic expansion by consolidating our operations in Latin America and expanding into key global markets. We are always looking for partnerships and new businesses, including acquisitions, licensing and joint ventures, that support our growth strategy.
To send a proposal, contact us: novosnegocios@eurofarma.com.br
Export
Eurofarma seeks to expand its geographic presence in several ways, including through exports to new markets. If you are looking for a supplier of high quality medicines for import, we will be happy to discuss partnership opportunities.
Get in touch by email: export@eurofarma.com.
CMO (Contract Manufacturing Organization)
We offer outsourcing solutions with excellence and innovation to meet the needs of your business. To explore opportunities and learn about our production capabilities, contact us by email: cmo@eurofarma.com
Out-Licensing Opportunities
In addition to seeking to increase the portfolio through partnerships of different models, we also evaluate partners who wish to license our differentiated products. Available products:
- Duomo HP® – Doxazosin + Finasteride | Indications: Benign Prostate Hyperplasia (BPH) and symptoms related to the disease
- Lugano®- Fluticasone + Formoterol | Indication: Regular treatment of adults and adolescents over 12 years of age with asthma
- Tamiram® – Levofloxacin 750mg (new concentration) | Indication: Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Complicated Urinary Tract Infections, Acute Pyelonephritis
- Versa® – Enoxaparin | Indication: Treatment of thrombosis, prevention of clotting of the extracorporeal circulation circuit during hemodialysis, treatment of unstable angina and acute myocardial infarction when administered with acetylsalicylic acid
- Heptar® – Heparin | Indication: Treatment and prophylaxis of thromboembolic disorders in patients with chronic kidney disease undergoing hemodialysis
Sponsorships
Through incentive laws, Eurofarma selects and supports projects focused on culture and sport, in addition to sponsoring other actions with its own resources, such as a Stock Car team.
For more information, click here, or contact us by email at patrocinios@eurofarma.com.br
Eurofarma's Experience
The strong performance with the sales and medical propaganda team, marketing and distribution capillarity are significant advantages over other companies. We have one of the largest sales and medical propaganda workforces in Latin America, with over 4,000 employees
Experience and regulatory knowledge help to effectively fulfill all local regulatory requirements. We are experts in pricing strategies and non-standard approval flows such as orphan drugs and fast track designations.
We believe that investing in the pursuit of incremental and radical innovation must be constant in order to always create new opportunities and position ourselves strategically in the pharmaceutical market, so we have a Radical Innovation nucleus with renowned scientists.
In 2019, the Eurofarma Innovation Center will begin operating in the Itapevi Industrial Complex in Greater São Paulo, housing projects related to radical innovation, biotechnology, biosimilar drugs and new technological platforms. Investments in the Center are estimated at BRL 155 million. Almost 750 professionals are currently dedicated to research and development.
We cover 82% of the Latin American market and are present in 20 countries in South and Central America, the Caribbean and Africa. We have 9 plants strategically distributed throughout Latin America, with 4 manufacturing plants in Brazil. The company’s entry to other countries is the best example of the extent to which we are committed to being the best option in regional partnerships, with own operations and integrated synergy among all nations. Internationalization planning includes about 200 countries in prospecting, studies or visits, with priorities for Africa and Asia.
We have a dedicated clinical team with experience in conducting studies on several different indications. Over the past three years, 99 clinical studies have been conducted with about 3,200 participants.